Albendazole therapy for neurocysticercosis.
Based on clinical evaluation and computed tomography (CT) of the brain, 30 cases of neurocysticercosis were diagnosed. Diagnosis was supported by presence of histopathologically proven subcutaneous cysticerci in 12 cases. Three primary neurological syndromes were established i.e. epilepsy in 22 cases, increased intracranial tension in 6 cases and meningoencephalitis in 2 cases. Albendazole was administered orally in a dose of 15 mg/kg bodyweight/day for 30 days without prophylactic steroids. Follow up CT study at 3 months and 12 months revealed complete regression of all lesions in 2 cases, partial regressions in 14 cases and change in morphology in 4 cases. Transient appearence of fresh subcutaneous cysticerci as a side effect of therapy was noted in 4 cases. Albendazole, though acting slow, is considered a suitable alternative to praziquantel in medical management of parenchymal neurocysticercosis.
Sanchetee
P C
PC
Armed Forces Medical College, Pune.
Venkataraman
S
S
Dhamija
R M
RM
Roy
A K
AK
D000293:Adolescent; D000328:Adult; D015766:Albendazole / Q000009:adverse effects / Q000627:therapeutic use*; D001927:Brain Diseases / Q000000981:diagnostic imaging / Q000188:drug therapy*; D002648:Child; D003551:Cysticercosis / Q000000981:diagnostic imaging / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D014057:Tomography, X-Ray Computed
D015766:Albendazole